Behrendt H, Brinkhuis M, Van Leeuwen E F
Department of Paediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Med Pediatr Oncol. 1996 Apr;26(4):244-8. doi: 10.1002/(SICI)1096-911X(199604)26:4<244::AID-MPO4>3.0.CO;2-J.
Seventeen previously untreated children with Hodgkin's disease were treated with six courses of the combination adriamycin, bleomycin, vinblastine, and DTIC (ABVD), without radiotherapy, from 1984-1987. In all patients, complete remission was attained. After a median follow-up period of 73.5 months (range 59-98 months) five patients had a relapse after 4, 5, 11, 21, and 34 months, respectively, from attainment of complete remission. In 12 patients with stages I and II, two relapses occurred. Three out of five patients with stage III and stage IV developed a relapse. Based upon these results, we conclude that ABVD might be an appropriate treatment for newly diagnosed children with Hodgkin's disease stages I and II. However, for children with stages III and IV more intensive treatment is needed. Radio-therapy should be withheld for children with refractory disease, residual disease, or relapse.
1984年至1987年期间,17名先前未经治疗的霍奇金病患儿接受了六个疗程的阿霉素、博来霉素、长春花碱和达卡巴嗪(ABVD)联合治疗,未进行放射治疗。所有患者均实现完全缓解。在中位随访期73.5个月(范围59 - 98个月)后,五名患者分别在达到完全缓解后的4、5、11、21和34个月出现复发。在12例I期和II期患者中,发生了两次复发。五例III期和IV期患者中有三例出现复发。基于这些结果,我们得出结论,ABVD可能是新诊断的I期和II期霍奇金病患儿的合适治疗方法。然而,对于III期和IV期患儿,需要更强化的治疗。对于难治性疾病、残留疾病或复发的患儿,应避免放疗。